Digipath
Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Herper went out of his way to misrepresent

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
iwfal Member Profile
Member Level 
Followed By 67
Posts 4,288
Boards Moderated 0
Alias Born 09/06/03
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 1/4/2019 4:43:20 PM
Amarin Provides Preliminary 2018 Results and 2019 Outlook GlobeNewswire Inc. - 1/4/2019 4:15:00 PM
Amarin to Present at 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 GlobeNewswire Inc. - 1/2/2019 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/30/2018 6:35:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/30/2018 6:34:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/29/2018 4:08:05 PM
Securities Registration (ads, Immediate) (f-6ef) Edgar (US Regulatory) - 11/29/2018 3:07:20 PM
Amarin to Participate in a Fireside Chat at Citi’s 2018 Global Healthcare Conference GlobeNewswire Inc. - 11/28/2018 6:25:36 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/28/2018 5:24:09 PM
Amarin Prices Public Offering of American Depositary Shares GlobeNewswire Inc. - 11/26/2018 8:59:19 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/26/2018 5:32:33 PM
Amarin Announces Proposed Public Offering of American Depositary Shares GlobeNewswire Inc. - 11/26/2018 4:23:58 PM
Amarin to Present at the Evercore ISI HealthCONx Conference GlobeNewswire Inc. - 11/20/2018 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/14/2018 6:03:51 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/13/2018 6:18:24 AM
Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stro... PR Newswire (US) - 11/11/2018 10:32:00 AM
Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stro... GlobeNewswire Inc. - 11/10/2018 3:00:00 PM
Amarin to Present at the Jefferies 2018 London Healthcare Conference GlobeNewswire Inc. - 11/8/2018 6:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/7/2018 4:13:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/2/2018 6:12:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/2/2018 6:12:30 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/1/2018 7:06:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/1/2018 7:05:12 AM
Amarin Reports Third Quarter 2018 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 11/1/2018 5:00:00 AM
Amarin Schedules Webcast Discussion of Primary REDUCE-IT™ Trial Results Following Presentation at 2018 Scientific Sessions ... GlobeNewswire Inc. - 10/26/2018 5:00:00 AM
iwfal Member Level  Saturday, 01/12/19 12:36:28 AM
Re: chas1232123 post# 171844
Post # of 172906 
Quote:
Herper went out of his way to misrepresent the facts in his November hit piece. His follow on article didn't really fix it. What he did was demonstrably wrong and indefensible.



You may not like it, but there was a substantial fraction of the cardio MD community that was extremely doubtful (presumably bc of the long history of failure). Most ppl, particularly KOLs, who tend to be older, don’t do paradigm shift well.

Prediction: it will happen again when they get the first positive Ph3 for one of the drugs that lowers stroke clotting wo increasing bleeds. It’s opportunity.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist